
Annual report 2022
added 12-21-2024
Genetron Holdings Limited Financial Ratios 2011-2026 | GTH
Annual Financial Ratios Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | -3.1 | -0.5 | -0.4 | -0.1 | -1.8 | - | - | - | - | - | - |
P/S |
- | 2.9 | 3.9 | 0.8 | 0.3 | 7.5 | - | - | - | - | - | - |
EPS |
- | -1.1 | -10.2 | -5.4 | -4.1 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
251 M | 1.21 B | 566 M | 2.46 B | 1.31 B | 1.18 B | - | - | - | - | - | - |
EBITDA per Share |
- | -1.12 | -3.97 | -4.53 | -3.37 | -1.97 | - | - | - | - | - | - |
EV/EBITDA |
-2.7 | -1.2 | -0.0 | -0.3 | -0.6 | - | - | - | - | - | - | |
PEG |
- | -0.0 | 0.05 | -0.2 | 0.18 | - | - | - | - | - | - | |
P/B |
- | 1.3 | 1.0 | -0.1 | -0.1 | -1.2 | - | - | - | - | - | - |
P/CF |
- | -2.9 | -5.5 | -1.3 | -0.3 | -0.8 | - | - | - | - | - | - |
ROE % |
- | - | -181.33 | 38.02 | 43.70 | 67.61 | - | - | - | - | - | - |
ROA % |
- | -33.12 | -155.80 | -117.88 | -143.32 | -95.28 | - | - | - | - | - | - |
ROCE % |
- | - | -15.41 | -85.06 | -90.77 | -38.95 | - | - | - | - | - | - |
Current Ratio |
2.3 | 4.9 | 7.1 | 0.2 | 0.2 | 8.1 | - | - | - | - | - | - |
DSO |
- | - | - | - | - | 122.3 | - | - | - | - | - | - |
DIO |
- | - | - | - | - | 62.8 | - | - | - | - | - | - |
DPO |
- | - | - | - | - | 43.5 | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | 185.1 | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | 141.6 | - | - | - | - | - | - |
All numbers in CNY currency
Quarterly Financial Ratios Genetron Holdings Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
- | - | - | - | 4.9 | - | - | - | 7.1 | - | - | - | 0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Multiples are an important financial analysis tool for the company Genetron Holdings Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Agilent Technologies
A
|
$ 112.78 | 0.68 % | $ 34.3 B | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Biomerica
BMRA
|
$ 2.13 | - | $ 4.89 M | ||
|
Fulgent Genetics
FLGT
|
$ 16.31 | -0.12 % | $ 493 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
$ 74.22 | -1.99 % | $ 5.01 B | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Medpace Holdings
MEDP
|
$ 457.05 | 0.03 % | $ 13.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 242.53 | 0.28 % | $ 25.6 B | ||
|
Myriad Genetics
MYGN
|
$ 4.59 | -1.61 % | $ 425 M | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Pacific Biosciences of California
PACB
|
$ 1.37 | -1.8 % | $ 411 M | ||
|
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Precipio
PRPO
|
$ 26.85 | -0.3 % | $ 34.8 M | ||
|
Personalis
PSNL
|
$ 7.51 | -1.38 % | $ 445 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | ||
|
RadNet
RDNT
|
$ 59.53 | -3.58 % | $ 4.48 B | ||
|
Charles River Laboratories International
CRL
|
$ 157.49 | -0.32 % | $ 7.81 B | ||
|
IQVIA Holdings
IQV
|
$ 164.98 | -1.19 % | $ 28.4 B | ||
|
Senseonics Holdings
SENS
|
$ 6.58 | -0.6 % | $ 275 M | ||
|
Sotera Health Company
SHC
|
$ 13.78 | -0.76 % | $ 3.91 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
$ 1.21 | -17.47 % | $ 6.59 M | ||
|
National Research Corporation
NRC
|
$ 17.47 | -0.26 % | $ 391 M | ||
|
Neuronetics
STIM
|
$ 1.54 | -4.06 % | $ 102 M | ||
|
Interpace Biosciences
IDXG
|
$ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
$ 572.18 | -1.09 % | $ 46 B | ||
|
Illumina
ILMN
|
$ 124.58 | 0.64 % | $ 19.8 B | ||
|
ICON Public Limited Company
ICLR
|
$ 99.8 | -0.55 % | $ 8.23 B | ||
|
Guardant Health
GH
|
$ 82.96 | -2.36 % | $ 10.4 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
$ 44.3 | -0.45 % | $ 2.65 B | ||
|
Celcuity
CELC
|
$ 100.81 | -5.57 % | $ 3.98 B | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 263.8 | -0.23 % | $ 21.9 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
ENDRA Life Sciences
NDRA
|
$ 3.41 | -2.16 % | $ 1.83 M | ||
|
NeoGenomics
NEO
|
$ 7.9 | -2.47 % | $ 1.01 B | ||
|
Natera
NTRA
|
$ 194.02 | -3.03 % | $ 19.1 B | ||
|
CareDx, Inc
CDNA
|
$ 17.35 | -1.2 % | $ 925 M | ||
|
OPKO Health
OPK
|
$ 1.14 | -1.3 % | $ 791 M |